Revenue GrowthSustained revenue expansion over multiple years signals durable demand across its branded formulations, exports and API segments. Strong top-line growth supports scale, market penetration and provides room to invest in registrations, commercialization and manufacturing capacity long-term.

Improved Gross MarginA materially higher gross margin points to manufacturing efficiency gains or better product mix, which are structural advantages in pharma manufacturing. Higher gross margins provide operating leverage, helping sustain profitability through price pressure or input-cost cycles over the medium term.

Low Leverage / Strong Equity BaseLow financial leverage and a growing equity base give the company balance-sheet flexibility to fund regulatory filings, geographic expansion and capex without overreliance on debt. This stability supports strategic investments and resilience through industry cycles.

Bears Say

Negative Operating & Free Cash FlowNegative operating and free cash flow indicate cash-generation weakness despite revenue growth. This can force reliance on external financing or working capital drawdowns, constraining reinvestment in launches, registrations and capacity and posing liquidity risk over the next several quarters.

Modest Net ProfitabilityA sub-10% net margin limits retained earnings and internal funding for R&D, regulatory compliance and commercial expansion. Modest profitability leaves less cushion against pricing pressure, input-cost inflation or one-time regulatory costs, weakening long-term earnings resilience.

Margin Volatility / Cash Conversion InconsistencyVolatile operating margins and inconsistent cash conversion complicate forecasting and capital planning. Structural unpredictability in profitability and cash flows raises execution risk for manufacturing scale-ups, product launches and sustaining regulatory-compliant operations over multiple quarters.

Unichem Laboratories Limited News

Unichem Laboratories Settles European Commission Fine

Unichem Laboratories Limited ( ($IN:UNICHEMLAB) ) has shared an update. Unichem Laboratories Limited has announced the payment of...

5M ago

Unichem Laboratories Faces Demand Notice from NPPA for Alleged Overcharging

The latest update is out from Unichem Laboratories Limited ( ($IN:UNICHEMLAB) ). Unichem Laboratories Limited has received a...

6M ago

Unichem Laboratories Receives USFDA Inspection Report

Unichem Laboratories Limited ( ($IN:UNICHEMLAB) ) just unveiled an announcement. Unichem Laboratories Limited announced that it has received...

7M ago

Unichem Laboratories Updates RTA Contact Details

Unichem Laboratories Limited ( ($IN:UNICHEMLAB) ) has provided an announcement. Unichem Laboratories Limited announced a change in the...

11M ago

UNICHEMLAB FAQ

What was Unichem Laboratories Limited’s price range in the past 12 months?

Unichem Laboratories Limited lowest stock price was ₹304.25 and its highest was ₹727.95 in the past 12 months.

What is Unichem Laboratories Limited’s market cap?

Unichem Laboratories Limited’s market cap is ₹21.71B.

When is Unichem Laboratories Limited’s upcoming earnings report date?

Unichem Laboratories Limited’s upcoming earnings report date is May 21, 2026 which is in 64 days.

How were Unichem Laboratories Limited’s earnings last quarter?

Unichem Laboratories Limited released its earnings results on Feb 05, 2026. The company reported ₹37.538 earnings per share for the quarter, beating the consensus estimate of N/A by ₹37.538.

Is Unichem Laboratories Limited overvalued?

According to Wall Street analysts Unichem Laboratories Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Unichem Laboratories Limited pay dividends?

Unichem Laboratories Limited pays a Annually dividend of ₹4 which represents an annual dividend yield of N/A. See more information on Unichem Laboratories Limited dividends here

What is Unichem Laboratories Limited’s EPS estimate?

Unichem Laboratories Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Unichem Laboratories Limited have?

Unichem Laboratories Limited has 70,405,754 shares outstanding.

What happened to Unichem Laboratories Limited’s price movement after its last earnings report?

Unichem Laboratories Limited reported an EPS of ₹37.538 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.969%.

Which hedge fund is a major shareholder of Unichem Laboratories Limited?

Currently, no hedge funds are holding shares in IN:UNICHEMLAB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Unichem Laboratories Limited

Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products worldwide. It offers formulation products that address various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infective, and pain management; and active pharmaceutical ingredients, as well as contract manufacturing services. The company was founded in 1944 and is headquartered in Mumbai, India.